Seriously ill patients in the US could soon have greater access to
experimental drugs if a planned regulatory overhaul by the Food and
Drug Administration (FDA) goes ahead.
The US Food and Drug Administration (FDA) has decided against
restricting the use of drug-eluting cardiac stents after a two-day
investigation into their potential to increase blood clots.
Dr Reddy's Laboratories has started first clinical trials of a
"four-in-one" polypill clinical trial, which could revolutionise
the cardiovascular drugs market.
Vion Pharmaceuticals has awarded a manufacturing agreement with
Ohio based contract manufacturers Ben Venue Laboratories to produce
its lead anticancer drug, Cloretazine (VNP40101M).
i3 has announced new plans to expand its pharmaceutical services
offerings across four continents - India, Latin America, and
Eastern and Western Europe.
Roche has invested $20m in a new technology that has the potential
to dramatically enhance the delivery of subcutaneous drugs by
acting like a 'molecular machete'.
Schwarz Pharma has awarded an engineering and procurement contract
to a Jacobs Engineering Group subsidiary for the development of a
new active pharmaceutical ingredient (API) manufacturing facility
in Ireland.
According to a review of public healthcare funding, the current
method of developing drugs is unsustainable and must be updated if
the UK is to remain at the forefront of European bioscience.
India is the first choice for foreign companies looking to offshore
their knowledge process outsourcing (KPO) activities and future
growth will be fuelled by the pharma market, according to a new
report.
Sufferers of Alzheimer's have received a boost with the news that
GlaxoSmithKine has ploughed further investment into developing new
drugs to combat the disease.
Pharmaceutical giant AstraZeneca has invested in a tablet
manufacturing plant in Egypt, which could form a launching pad for
an expansion into emerging markets.
Three failed clinical trials on two different drug candidates in a
week are bad enough for Bayer but it is their collaborators who are
really suffering.
Biologic drug manufacturing is slowly starting to take off in
Singapore and is expected to be a key component of the country's
drug manufacturing activity in the future.
The first radio frequency identification (RFID) tag that can resist
gamma irradiation has been developed to track pharmaceutical
products early on and throughout the supply chain.
Almost 130 jobs will be lost at BASF's Minden site as the company
succumbs to growing pressure from the Asian generic active
pharmaceutical ingredient (API) market.
US researchers have developed a novel delivery vehicle for siRNA,
an up-and-coming technology for switching off genes in the body
that could accelerate its use in drug development.
A new 'glass' making technique that improves stability and
durability could lead to novel coatings and improvements in drug
delivery, according to researchers at the University of
Wisconsin-Madison and the National Institute...
Fine chemicals maker Siegfried Holdings has agreed to sign over
part of the production capacity of its Zofingen production plant to
US biotech Celgene Corp in a collaboration worth €34.9m.
A leading Alzheimer's expert has pleaded guilty to a conflict of
interest charge relating to money he received from a pharmaceutical
company while conducting research for the US government.
The US Senate has confirmed Andrew von Eschenbach as the official
Commissioner of the Food and Drug Administration (FDA) after months
of delay due to complaints about the regulator's oversight.
Dutch researchers have developed a new way of making a Parkinson's
disease drug using an inexpensive ionic liquid method that could
yield cost savings of €11.3 million per annum.
Onyx Pharmaceuticals have fallen out of the race to find a badly
needed new treatment for skin cancer after their lead drug tripped
up in its final stage clinical trial.
Baxter is expanding its lyophilisation capacity at its German
facility to support future growth of its contract manufacturing
business for anti-cancer drugs.
Galapagos is to spend up to €19.1m to acquire Inpharmatica in order
to accelerate their drug discovery capabilities, especially in the
early stages of development.
Indian pharma firm Panacea Biotec has taken a 10 percent stake in
UK-based vaccine maker Cambridge Biostability (CBL) for £1.9m
(€1.4m) under a new joint venture deal signed between the two
companies.
Packaging maker Alcan has announced it will invest $27.5m (€20.7m)
for an expansion project in its US pharma centre to meet the
growing demand for pharmaceutical flexible packaging materials.
The UK subsidiary of ProMetic Life Sciences has signed a deal with
Novartis to develop a new purification technology for recombinant
protein vaccines that is claimed to be more efficient and cheaper
than currently used methods.
Intertek has broadened its portfolio to offer outsourced analysis of biologics as well as small molecules by purchasing Alta Laboratories, for $25m (€18.8m).
Before deciding what part of a clinical trial to outsource, one of
the most important things a sponsor should do is define its core
competencies and then outsource accordingly.
Nastech missed out on a $15m (€11m) milestone payment after having
to delay the development of its new nasal spray for the treatment
of osteoporosis because of the need of an additional clinical
trial.